Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

PURPOSE: To conduct a first-in-human phase I study to determine the dose-limiting toxicities (DLT), characterize the pharmacokinetic profile, and document the antitumor activity of IPI-926, a new chemical entity that inhibits the Hedgehog pathway (HhP). EXPERIMENTAL DESIGN: Patients with solid tumor...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Jimeno, Antonio, Weiss, Glen J., Miller, Wilson H., Gettinger, Scott, Eigl, Bernard J.C., Chang, Anne Lynne S., Dunbar, Joi, Devens, Shannon, Faia, Kerrie, Skliris, Georgios, Kutok, Jeff, Lewis, Karl D., Tibes, Raoul, Sharfman, William H., Ross, Robert W., Rudin, Charles M.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2013
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3694426/
https://ncbi.nlm.nih.gov/pubmed/23575478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-3654
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन